J&J MedTech rolls out TECNIS PureSee intraocular lens in EMEA

2024-02-16

The TECNIS PureSee presbyopia-correcting intraocular lens (IOL) features a unique, purely refractive design that offers uninterrupted, high-quality, vision with high contrast and low-light performance, comparable to a monofocal IOL Johnson & Johnson MedTech’s TECNIS PureSee IOL. (Credit: Johnson & Johnson MedTech) Johnson & Johnson MedTech, a company of Johnson and Johnson (J&J), has launched its TECNIS PureSee presbyopia-correcting intraocular lens (IOL) in the Europe, Middle East and Africa (EMEA) region. The TECNIS PureSee features a unique, purely refractive design that offers uninterrupted, high-quality, vision with high contrast and low-light performance, comparable to a monofocal IOL. According to J&J MedTech, surgeons and patients make trade-off decisions when choosing an IOL, considering its clear sight, spectacles, price, and possible glares and halos. Its TECNIS PureSee IOL will address the issues and improve the overall outcomes for both patients and surgeons, said the eye health technology company. Johnson & Johnson Vision EMEA president Jacqueline Henderson said: “Cataract surgery is the number one surgery performed globally, with 28 million procedures each year. “But only 10-15% of patients are getting advanced optical IOLs specifically designed for astigmatism and presbyopia. “Today, we’re proud to launch the TECNIS PureSee IOL, giving surgeons and patients the choice of a premium IOL that combines clarity of vision and reduced visual symptoms.” Building on its purely refractive design, TECNIS PureSee IOL ensures surgeons’ ease of use in providing high tolerance to refractive error. It offers important benefits, including uninterrupted high-quality vision, with superior distance and intermediate vision, along with functional near vision for spectacle independence. TECNIS PureSee has a dysphotopsia pro is comparable to a monofocal IOL in frequency, having little to no visual symptoms, such as halos, glares, and starbursts. Furthermore, a surgeon can remove a cataract, which is a major cause of treatable blindness, and replace it with an IOL to restore the patient’s sight the very same day, said the company. Advalia Vision CEO, medical director and physician Francesco Carones said: “My early experience with the TECNIS PureSee IOL has been extremely positive and has consistently delivered on these expectations resulting in very happy patients. “I’ve found that this new refractive PC-IOL reliably delivers consistent, uninterrupted, high-quality vision with excellent distance vision and high contrast not only in daylight but also at night. “Together with the low level of dysphotopsia, that is comparable to a monofocal IOL, these are exactly the results my patients are looking for. So, I’m thrilled to be able to offer them the ability to correct presbyopia with this new lens technology.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构